Conjugation Sample Clauses

Conjugation. The AFAIK2 product from the first engineering batch will be conjugated with 50 grams of high purity urease. The final product will be prepared in a stabilized buffer solution, the nature of the ingredients to be provided by Helix. The conjugated product will be available for use by Helix as well as be available to complete the qualification for the majority of the release tests, with others as FIO since the stability of the product prior to conjugation has not been established. The product will also be used for packaging trials of the bulk drug substance in the selected packaging container for shipment to the formulator. Site cGMP API Facility, Class 100K clean room Time 2 days Documentation Preliminary batch records and notebooks to prepare product against target specifications, draft QC test methods and procedures. Deliverables 50 grams L-DOS47 , Completed batch records, QC reports Development report, Draft Certificate of analysis 5.4 L-DOS-47 Engineering Batch #2
AutoNDA by SimpleDocs
Conjugation. The AFAIK2 product from the second engineering batch will be conjugated with 50 grams of high purity urease. The final product will be prepared in a stabilized buffer solution, the nature of the ingredients to be provided by Helix. It is BioVectra’s understanding that the second engineering batch will be used as the toxicological batch. As such this batch will be used for the early stability study, as the batch prior to the clinical batch and a portion of this batch will allocated accordingly. The final product will be released against the same tests as proposed for the future clinical batch. Site cGMP API Facility, Class 100K clean room Time 2 days Documentation Batch records and notebooks to prepare product against target specifications, QC test methods and procedures. Deliverables 50 grams L-DOS47, Completed batch records, QC reports Development report, Certificate of analysis 5.5 L-DOS-47 Clinical Batch
Conjugation. During conjugate preparation, the single cysteine mutants will form Au-S bonds with AuNPs and the His tag mutant will strongly associate with the His-Tag. Each mutant was rehydrated with 1.42 mg/mL TCEP, to prevent disulfide bonds from forming,30 and were left to incubate for at least an hour. To make 5 nm conjugates, 400 L of 2.40 nM 5 nm AuNPs were added to 30 L of 50 mM free protein in a lo-bind Eppendorf tube and left to incubate overnight at 4°C to allow the conjugation to occur. The samples were centrifuged for 90 minutes at 13,200 rpm. The supernatant was removed, and the pellet was replenished with 0.005% Tween in 10 mM sodium phosphate buffer to wash the free protein from the pellet of DHFR-AuNP conjugates. After wash cycles, the pellet was stored in 0.005% Tween in 10 mM sodium phosphate buffer, and diluted accordingly. To make 15 nm conjugates, the same methods to make 5 nm conjugates were made except centrifuging speeds and times were changed to 8000 rpm and 35 minutes for 800 L of 7.88 nM 15 nm AuNP. To make 30 nm conjugates, the same methods to make 5 nm conjugates were made except centrifuging speeds and times were changed to 8000 rpm and 10 minutes for 400 L of 2.40 nM 15 nm AuNP.

Related to Conjugation

  • Licensed Technology The term "Licensed Technology" shall mean the ------------------- Licensed Patents, plus all improvements thereto developed by Licensor, and all related data, know-how and technology.

  • Manufacture 2.1. The LED(s) on the LED module shall be equipped with suitable fixation elements.

  • Licensed Product “Licensed Product” shall mean any article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights. For clarity, a “Licensed Product” shall not include other product or material that (a) is used in combination with Licensed Product, and (b) does not constitute an article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights.

  • Joint Technology The Parties agree that, in order to effectuate the provisions of Section 4.4.2, subject to any exclusive licenses granted hereunder, (a) the non-use provisions of this Article 9 shall not apply to each Party’s use of Joint Technology, and (b) each Party may disclose the Joint Technology to Third Parties who are under terms of confidentiality no less strict than those contained in this Agreement.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Combination Product The term “

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Know-How The term “

  • Background Technology List here prior contracts to assign Inventions that are now in existence between any other person or entity and you. [ ] List here previous Inventions which you desire to have specifically excluded from the operation of this Agreement. Continue on reverse side if necessary.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!